Logo image of CTLT

Catalent Inc (CTLT) Stock Fundamental Analysis

USA - NYSE:CTLT - US1488061029 - Common Stock

63.48 USD
0 (0%)
Last: 12/17/2024, 8:52:12 PM
63.5 USD
+0.02 (+0.03%)
After Hours: 12/17/2024, 8:52:12 PM
Fundamental Rating

3

Overall CTLT gets a fundamental rating of 3 out of 10. We evaluated CTLT against 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CTLT have multiple concerns. CTLT has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

CTLT had positive earnings in the past year.
CTLT had a positive operating cash flow in the past year.
In multiple years CTLT reported negative net income over the last 5 years.
In the past 5 years CTLT always reported a positive cash flow from operatings.
CTLT Yearly Net Income VS EBIT VS OCF VS FCFCTLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B

1.2 Ratios

With a decent Return On Assets value of -4.25%, CTLT is doing good in the industry, outperforming 78.01% of the companies in the same industry.
CTLT has a better Return On Equity (-11.66%) than 75.92% of its industry peers.
Industry RankSector Rank
ROA -4.25%
ROE -11.66%
ROIC N/A
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
CTLT Yearly ROA, ROE, ROICCTLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

1.3 Margins

CTLT has a Gross Margin (21.82%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of CTLT has declined.
CTLT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
CTLT Yearly Profit, Operating, Gross MarginsCTLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

3

2. Health

2.1 Basic Checks

CTLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTLT has more shares outstanding
CTLT has more shares outstanding than it did 5 years ago.
CTLT has a worse debt/assets ratio than last year.
CTLT Yearly Shares OutstandingCTLT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CTLT Yearly Total Debt VS Total AssetsCTLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

Based on the Altman-Z score of 1.62, we must say that CTLT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.62, CTLT is in the better half of the industry, outperforming 64.92% of the companies in the same industry.
CTLT has a debt to FCF ratio of 49.84. This is a negative value and a sign of low solvency as CTLT would need 49.84 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 49.84, CTLT is in the better half of the industry, outperforming 78.01% of the companies in the same industry.
A Debt/Equity ratio of 1.38 is on the high side and indicates that CTLT has dependencies on debt financing.
CTLT's Debt to Equity ratio of 1.38 is on the low side compared to the rest of the industry. CTLT is outperformed by 74.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 49.84
Altman-Z 1.62
ROIC/WACCN/A
WACC9.31%
CTLT Yearly LT Debt VS Equity VS FCFCTLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 2.51 indicates that CTLT has no problem at all paying its short term obligations.
CTLT has a Current ratio (2.51) which is comparable to the rest of the industry.
CTLT has a Quick Ratio of 1.93. This is a normal value and indicates that CTLT is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.93, CTLT is in line with its industry, outperforming 44.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.51
Quick Ratio 1.93
CTLT Yearly Current Assets VS Current LiabilitesCTLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

4

3. Growth

3.1 Past

CTLT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -61.40%.
CTLT shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -33.48% yearly.
The Revenue has been growing slightly by 4.71% in the past year.
The Revenue has been growing by 11.71% on average over the past years. This is quite good.
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%

3.2 Future

Based on estimates for the next years, CTLT will show a very strong growth in Earnings Per Share. The EPS will grow by 73.38% on average per year.
The Revenue is expected to grow by 7.44% on average over the next years.
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CTLT Yearly Revenue VS EstimatesCTLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B
CTLT Yearly EPS VS EstimatesCTLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1 2 3 4 5

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 288.55, which means the current valuation is very expensive for CTLT.
CTLT's Price/Earnings ratio is a bit cheaper when compared to the industry. CTLT is cheaper than 78.01% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.83, CTLT is valued quite expensively.
CTLT is valuated quite expensively with a Price/Forward Earnings ratio of 41.25.
Based on the Price/Forward Earnings ratio, CTLT is valued a bit cheaper than 76.44% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 32.68, CTLT is valued a bit more expensive.
Industry RankSector Rank
PE 288.55
Fwd PE 41.25
CTLT Price Earnings VS Forward Price EarningsCTLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200 250

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CTLT is valued a bit cheaper than 76.96% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CTLT is valued a bit cheaper than the industry average as 78.53% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 116.39
EV/EBITDA 36.47
CTLT Per share dataCTLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CTLT's earnings are expected to grow with 113.64% in the coming years.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y148.11%
EPS Next 3Y113.64%

0

5. Dividend

5.1 Amount

No dividends for CTLT!.
Industry RankSector Rank
Dividend Yield N/A

Catalent Inc

NYSE:CTLT (12/17/2024, 8:52:12 PM)

After market: 63.5 +0.02 (+0.03%)

63.48

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2024-11-05/bmo
Earnings (Next)02-07 2025-02-07/amc
Inst Owners92.2%
Inst Owner Change-100%
Ins Owners0.48%
Ins Owner Change0%
Market Cap11.52B
Revenue(TTM)4.42B
Net Income(TTM)-413.00M
Analysts52.86
Price Target64.77 (2.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-149.78%
Min EPS beat(2)-336.02%
Max EPS beat(2)36.46%
EPS beat(4)1
Avg EPS beat(4)-365.14%
Min EPS beat(4)-1032.86%
Max EPS beat(4)36.46%
EPS beat(8)2
Avg EPS beat(8)-208.81%
EPS beat(12)5
Avg EPS beat(12)-141.22%
EPS beat(16)9
Avg EPS beat(16)-103.51%
Revenue beat(2)1
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-5.19%
Max Revenue beat(2)4.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-6.04%
Max Revenue beat(4)4.16%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)6
Avg Revenue beat(12)-0.33%
Revenue beat(16)8
Avg Revenue beat(16)-0.03%
PT rev (1m)0.11%
PT rev (3m)4.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-43.12%
EPS NY rev (1m)4.18%
EPS NY rev (3m)-6.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.9%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.69%
Valuation
Industry RankSector Rank
PE 288.55
Fwd PE 41.25
P/S 2.61
P/FCF 116.39
P/OCF 28.88
P/B 3.25
P/tB 31.57
EV/EBITDA 36.47
EPS(TTM)0.22
EY0.35%
EPS(NY)1.54
Fwd EY2.42%
FCF(TTM)0.55
FCFY0.86%
OCF(TTM)2.2
OCFY3.46%
SpS24.36
BVpS19.51
TBVpS2.01
PEG (NY)0.82
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.25%
ROE -11.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.82%
FCFM 2.24%
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
F-Score5
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 49.84
Debt/EBITDA 11.05
Cap/Depr 61.22%
Cap/Sales 6.78%
Interest Coverage N/A
Cash Conversion 90.27%
Profit Quality N/A
Current Ratio 2.51
Quick Ratio 1.93
Altman-Z 1.62
F-Score5
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)125.99%
Cap/Depr(5y)159.79%
Cap/Sales(3y)11.57%
Cap/Sales(5y)13.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
EBIT growth 1Y-166.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year196.68%
EBIT Next 3Y58.17%
EBIT Next 5Y41.23%
FCF growth 1Y121.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y116.85%
OCF growth 3Y-14.78%
OCF growth 5Y1.59%

Catalent Inc / CTLT FAQ

What is the ChartMill fundamental rating of Catalent Inc (CTLT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CTLT.


What is the valuation status for CTLT stock?

ChartMill assigns a valuation rating of 4 / 10 to Catalent Inc (CTLT). This can be considered as Fairly Valued.


What is the profitability of CTLT stock?

Catalent Inc (CTLT) has a profitability rating of 3 / 10.


What are the PE and PB ratios of Catalent Inc (CTLT) stock?

The Price/Earnings (PE) ratio for Catalent Inc (CTLT) is 288.55 and the Price/Book (PB) ratio is 3.25.


What is the earnings growth outlook for Catalent Inc?

The Earnings per Share (EPS) of Catalent Inc (CTLT) is expected to grow by 350.55% in the next year.